Immunovant, Inc. (IMVT) Dividend History

Company News

• IMVT Stock Up on Upbeat Data From Graves' Disease Study of Batoclimab

  Immunovant's (IMVT) investigational candidate, batoclimab, showed positive data in a mid-stage study for Graves' Disease, leading to a rise in the company's stock. The data demonstrated significant reductions in Immunoglobin G levels and high response rates in the patient population.

  Benzinga

  Featured Companies: FULC ILMN KRYS
• Immunovant Provides Update on Graves’ Disease Development Program

  Immunovant's batoclimab achieved a 76% response rate in Graves' Disease patients uncontrolled on antithyroid drugs (ATDs) at week 12. The company also reported a strong correlation between IgG lowering and clinical outcomes, indicating a potential best-in-class and first-in-class opportunity for IMVT-1402 in Graves' Disease.

  GlobeNewswire Inc.
• Immunovant (IMVT) Down 1.6% Since Last Earnings Report: Can It Rebound?

  Immunovant (IMVT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  Zacks Investment Research
• 5 Biotech Stocks That Could Be Big Winners in 2024 and Beyond

  These five biotech companies could have a lot of room to run.

  The Motley Fool

  Featured Companies: AMGN CRSP